ArticleScientific reports2025
Metabolomic profiling of serum alterations and biomarker discovery in feline hepatic liposis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluation of Serum Homocysteine and High-Sensitivity Cardiac Troponins in Cats with Hepatic Lipidosis: An Observational Clinical Study.Veterinary sciences · 2026Article
- A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus.Journal of veterinary internal medicine · 2026Article
- Serum metabolomics identifies metabolic changes in obese cats fed enzymatically hydrolyzed poultry byproduct meal.Journal of veterinary internal medicine · 2026Article
- Preliminary metabolic characterization of hepatic lipidosis in cats using liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry: pathway insights and candidate biomarkers.Journal of veterinary internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Feline hepatic lipidosis (FHL) is a common liver dysfunction caused by metabolic disorders. The objective was to evaluate the metabolic alteration in the cats of FHL and to identify biomarkers that can serve as biomarker for FHL. Differential metabolites in the serum of spontaneous FHL cats (FS, n = 12) and healthy cats (CS group, n = 12) were analyzed using GC/MS metabolomics. Differential metabolites with diagnostic significance were identified through receiver operating characteristic (ROC) curves. The expression level of the differential metabolite 2-hydroxybutyric acid (2-HB) was detected in the serum of the FS and CS groups, and biomarker were established. The biomarker efficacy of 2-HB for FHL was verified using serum samples from cats with FHL caused by different etiologies (F, n = 10) and healthy cats (C, n = 50). There were 13 significantly different metabolites between the CS and FS groups (VIP > 1, P < 0.05) with the area under the ROC curve (AUC) greater than 0.70. The AUC for serum 2-HB was 0.90 (95% confidence interval 0.767-1.000, P < 0.001), with an optimal critical value of 564.8 ng/L. By randomly detecting serum 2-HB in groups F and C (the optimal cut-off value is 564.8 ng/L), the detection rate for FHL diagnosis was 100% and the false positive rate was 0%. In cats with FHL, metabolic changes occur in amino acids, nucleotide sugars, glycerophospholipids, phenylalanine, galactose, alpha-linolenic acid, and glycerides. A serum 2-HB level greater than 564.8 ng/L serves as a biomarker for FHL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.